Abstract
Background and aims Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) is a highly transmissible virus causing Coronavirus disease (COVID-19). Its symptoms include fever, dry cough, and shortness of breath. Vaccine plays a significant role in controlling infectious disease and lesser health resources are used, and there is increased allocation of those resources for disease management. Vero Cell is an inactivated vaccine against COVID-19 manufactured by Sinopharm Company of China and recommended for people above 18 years by the World Health Organization. It is administered in two doses of 0.5 ml, 14-28 days apart. The goal of our study was to determine post-vaccination side effects of both the first(1st) and the second(2nd) dose among participants of Nepalgunj Medical College Teaching Hospital (NGMCTH), Kohalpur, Banke, Nepal.
Methods A prospective cross-sectional study was conducted among undergraduate medical students and intern doctors of Nepalgunj Medical College. A comprehensive structured questionnaire was designed and distributed following each dose of vaccination. Data were collected from 6th January 2022 to 6th April 2022 and entered in Microsoft Excel and analyzed using the statistical package for social sciences (SPSS) version 22. Analyzed data were presented using simple descriptive statistics with appropriate tables.
Results Out of 156 participants, the majority were males (66.7%), within the age group of 21-24. The most frequently encountered symptom was pain at the injection site, predominantly seen in males. Among all the tested variables, the second dose of vaccination showed a significant association with sex. All the predominant symptoms exhibited a significant association following vaccination, except for pain at the injection site (p-value <0.05).
Conclusions Vaccine has proven to be a lifesaving breakthrough during the peak of the COVID-19 outbreak and has been precisely efficacious in a developing country like Nepal.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRC of Nepalgunj Medical College gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
We revisited and re-entered the data after being rejected at PLOS One journal due to simple statistics. We have now analyzed the data and made associations with categorical variables with symptoms, also symptoms with the frequency of vaccination were also analyzed.
Data Availability
All data produced in the present study are available upon reasonable request to the authors